Short answer
A medical device go-to-market strategy defines the narrow beachhead you will win first, the reimbursement conditions that must be true for that segment, the sales model you can actually afford, and the metrics that prove the motion repeats. Strategy is the choice of where to compete; the plan is the calendar that follows it.
GTM strategy vs. GTM plan
The strategy is the beachhead decision: which procedure, which geography, which account tier, and what makes you the better choice there specifically. The plan is the sequence of activities — reps hired, KOLs engaged, reference sites built — that executes the strategy. Teams that skip straight to the plan end up with a busy sales calendar and no clear answer to "why should this specific hospital switch to us."
Defining your beachhead
A workable beachhead is narrow on purpose: one procedure area, one geography where you have or can build reference relationships, and one account tier where the switching cost is genuinely low — not just where the clinical fit looks good on paper.
Reimbursement as a GTM gate, not an afterthought
If coverage and payment aren't resolved for your target accounts before the sales motion starts, every meeting ends at the same objection. Reimbursement clarity should gate which accounts enter the beachhead, not get solved reactively after a hospital says yes clinically. This is exactly where PROCEPT's patience paid off: as hospitals gained financial clarity around the procedure, the capital investment became easier to justify, and confidence compounded alongside the clinical evidence. More on this in our guide to medical device market access.
Choosing a sales model
Direct
Control and account intelligence, but capital-intensive and slow to scale geographically.
Distributor
Scales faster, but hands over the account relationship and the data that comes with it.
Hybrid
Direct in the beachhead where reference-building matters, distributor-supported once the model is proven.
Most successful medtech GTM plans converge on the hybrid model, including PROCEPT's expansion pattern after its initial adoption phase.
Metrics to track in the first 12 months
Installed systems or signed contracts are lagging vanity metrics on their own. Track instead: repeat utilization per account (not just placement), time from install to first repeat case, reference-site conversations generated per quarter, and reimbursement approval rate by account and region. Aquablation's early adoption data made this point directly — system placement created the appearance of traction, but repeat procedure volume is what proved whether that traction was real.
The execution question
A beachhead strategy is only as good as the account-level evidence behind it: which accounts actually fit the procedure and geography you've chosen, which have a resolvable reimbursement picture, and which already have a champion who can become a reference. Building that evidence by hand for each candidate account is what turns a sound GTM strategy into a slow GTM plan.
RevWorx ranks and evidences your beachhead accounts directly, so the strategy and the plan move at the same speed instead of one waiting on the other. See the wider picture on our medical device commercialization strategy page.
Sources and notes
- Asensus Surgical / Senhance: FDA clearance (2017) and the 2024 acquisition by KARL STORZ for approximately $95 million are public record. See Business North Carolina and Asensus's acquisition announcement. The framing of Senhance's difficulty as a switching-cost problem rather than a clinical one is our interpretation of the public record, not a direct quote.
- PROCEPT BioRobotics / AquaBeam: the 2017 De Novo clearance and continued growth are public. See the FDA De Novo classification and PROCEPT's FY2024 10-K. The adoption-program details reflect industry-standard practice described in secondary coverage rather than a single published playbook.
Frequently asked questions
- What is a beachhead in medtech GTM?
- The smallest segment where your evidence, reimbursement, and workflow fit are all strong at once — often one procedure type, one site of care, and one payer environment. Winning it produces reference accounts that make the next segment easier.
- Why is reimbursement a gate rather than a later step?
- If there is no code, no coverage, or no adequate payment for your indication in a target region, the account cannot buy regardless of clinical enthusiasm. Reimbursement should qualify or disqualify a segment before you invest sales effort in it.
- Direct sales reps or distributors for a new device?
- Direct reps give control and learning but cost roughly $250K+ fully loaded per rep with long ramp. Distributors buy reach cheaply but rarely prioritize a new product without pull. Most early teams run a small direct team in the beachhead and consider distribution only after the motion is proven.
- What metrics matter in the first 12 months?
- Accounts entered into value analysis review, time from first meeting to committee, pilot-to-contract conversion, reorder or utilization rate at live sites, and revenue per account — not raw lead counts.